Trial Profile

A Study of B-cell Maturation Antigen/Cluster of Differentiation Antigen 19 Dual-Target Chimeric Antigen Receptor T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 31 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 0120 (Primary) ; Cyclophosphamide; Fludarabine
Indications Multiple myeloma; Plasma cell leukaemia
Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

15 Jun 2023 Updated results presented at the 28th Congress of the European Haematology Association
10 Jun 2023 According to a Gracell Biotechnology media release, data from this study were presented at the European Hematology Association (EHA2023) Congress.
10 Jun 2023 Results presented in Gracell Biotechnology Media Release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com